Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Raised to “Hold” at The Goldman Sachs Group

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) was upgraded by stock analysts at The Goldman Sachs Group to a “hold” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

Shionogi & Co., Ltd. Unsponsored ADR Price Performance

Shionogi & Co., Ltd. Unsponsored ADR stock opened at $10.94 on Wednesday. Shionogi & Co., Ltd. Unsponsored ADR has a 1 year low of $7.27 and a 1 year high of $12.00. The firm has a 50 day moving average price of $11.05 and a 200 day moving average price of $9.52. The company has a market cap of $18.61 billion, a price-to-earnings ratio of 14.39, a PEG ratio of 0.87 and a beta of 0.19. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.21 and a current ratio of 5.84.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last released its earnings results on Friday, January 30th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.19 by $0.09. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 41.82% and a return on equity of 13.70%. The firm had revenue of $966.53 million during the quarter, compared to the consensus estimate of $848.42 million. Sell-side analysts predict that Shionogi & Co., Ltd. Unsponsored ADR will post 0.66 earnings per share for the current year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.